oral
anticoagul
therapi
warfarin
primari
treatment
patient
risk
thrombosi
highli
effect
role
vitamin
k
antagonist
administr
reduct
thromboembol
event
extens
document
howev
use
anticoagul
coupl
increas
risk
bleed
complic
annual
risk
gastrointestin
urinari
tract
bleed
also
intracrani
haemorrhag
ich
increas
anticoagul
popul
annual
fatal
rate
potenti
seriou
natur
complic
mean
effect
rapid
treatment
vitamin
k
antagonist
revers
requir
one
therapeut
option
manag
vitamin
k
antagonist
revers
fourfactor
prothrombin
complex
concentr
pcc
pcc
contain
combin
coagul
factor
inhibit
vitamin
k
antagonist
factor
f
ii
vii
ix
x
protein
c
z
pcc
administr
concomit
vitamin
k
recommend
facilit
emerg
revers
oral
anticoagul
also
use
treat
case
coagul
defect
relat
liver
diseas
also
acquir
defici
vitamin
kdepend
coagul
factor
periop
set
combin
age
popul
thu
increas
number
anticoagul
patient
also
increas
administr
pcc
across
wider
rang
indic
mean
efficaci
safeti
product
current
focu
grow
number
studi
shown
pcc
facilit
rapid
predict
revers
vitamin
k
antagonist
therapi
patient
acut
bleed
requir
emerg
surgeri
despit
efficaci
widespread
use
pcc
hamper
concern
safeti
clot
factor
concentr
blood
plasmaderiv
product
thrombogen
potenti
pathogen
transmiss
primari
safeti
consider
relat
pcc
administr
investig
safeti
treatment
sinc
market
author
analysi
pharmacovigil
data
relat
beriplex
pn
csl
behr
gmbh
marburg
germani
administr
present
first
time
data
updat
previous
present
congress
intern
societi
thrombosi
haemostasi
furthermor
includ
review
recent
studi
involv
commerci
avail
fourfactor
pcc
undertaken
establish
efficaci
safeti
profil
product
across
rang
clinic
set
beriplex
pn
licens
across
europ
broad
rang
indic
includ
revers
vitamin
k
antagonist
therapi
clot
factor
supplement
sever
liver
diseas
treatment
acquir
bleed
sinc
februari
retrospect
review
global
pharmacovigil
databas
csl
behr
februari
march
perform
sourc
spontan
report
case
report
scientif
literatur
includ
publish
case
report
investigatoriniti
clinic
trial
applic
nonintervent
postauthor
studi
suspect
advers
reaction
possibl
relat
beriplex
pn
administr
identifi
inform
regard
clinic
use
beriplex
pn
includ
indic
dosag
also
collat
ethic
approv
requir
studi
literatur
review
perform
assess
efficaci
safeti
commerci
avail
pcc
literatur
search
perform
use
pubm
onlin
search
tool
search
term
appli
across
search
field
prothrombin
complex
concentr
safeti
prothrombin
complex
concentr
efficaci
prothrombin
complex
concentr
revers
prothrombin
complex
concentr
thrombosi
prothrombin
complex
concentr
embol
report
clinic
trial
report
advers
event
ae
februari
march
review
relev
inform
relat
clinic
indic
product
efficaci
ae
relat
pcc
administr
identifi
total
iu
beriplex
pn
administ
observ
period
assum
averag
dose
iu
per
patient
infus
perform
treat
number
indic
includ
vitamin
k
antagonist
revers
clot
factor
supplement
liver
diseas
consid
primari
safeti
concern
relat
allogen
administr
analysi
safeti
review
show
report
either
viral
transmiss
heparininduc
thrombocytopenia
hit
type
ii
relat
beriplex
pn
administr
tabl
total
case
suspect
thromboembol
event
record
tabl
occur
patient
receiv
beriplex
pn
anticoagul
revers
analysi
event
reveal
preexist
concomit
condit
like
result
thromboembol
present
patient
within
context
total
infus
perform
ratio
thromboembol
event
per
infus
report
review
literatur
demonstr
efficaci
safeti
profil
sever
fourfactor
pcc
use
revers
vitamin
k
antagonist
therapi
supplement
coagul
factor
liver
diseas
treatment
traumarel
bleed
evalu
summari
nine
prospect
studi
shown
tabl
incid
seriou
ae
record
case
viral
transmiss
thromboembol
event
highlight
four
case
thrombot
event
report
studi
identifi
two
beriplex
pn
also
captur
analysi
pharmacovigil
data
tabl
three
case
seroconvers
parvoviru
report
use
octaplex
w
octapharma
lachen
switzerland
addit
three
thromboembol
event
cerebr
infarct
pulmonari
embol
embol
brachial
arteri
potenti
associ
pcc
administr
describ
retrospect
pilot
studi
patient
undergo
aortic
arch
replac
acut
type
aortic
dissect
patient
studi
underw
prolong
cardiopulmonari
bypass
includ
isol
head
perfus
phase
deep
hypotherm
tabl
male
patient
metastat
gastrointestin
cancer
arrhythmia
absoluta
treat
market
beriplex
pn
iu
clinic
studi
patient
alreadi
receiv
studi
drug
also
beriplex
pn
need
second
infus
pcc
thu
treat
market
batch
beriplex
pn
studi
drug
patient
experienc
short
breath
die
day
later
caus
death
suspect
pulmonari
embol
thromboembol
event
report
group
thromboelastometryguid
therapi
case
patient
sever
ill
potenti
prothrombot
state
fact
high
level
blood
product
administr
mean
reason
report
thrombot
event
undetermin
howev
pcc
rule
potenti
caus
gener
pcc
review
found
effect
correct
intern
normal
ratio
inr
anticoagul
patient
cessat
sever
bleed
within
emerg
set
rapid
correct
vitamin
k
antagonist
therapi
requir
patient
major
bleed
invas
surgeri
evan
colleagu
carri
prospect
analysi
anticoagul
patient
requir
vitamin
k
antagonist
revers
pcc
administr
result
immedi
cessat
bleed
satisfactori
clinic
respons
patient
data
oper
patient
made
slow
neurolog
recoveri
eight
day
postop
ct
scan
show
small
peripher
infarct
cerebellar
hemispher
bilater
corrobor
larger
prospect
studi
correct
inr
observ
within
min
pcc
administr
rapid
infus
pcc
median
dose
iu
kg
total
infus
time
min
use
immedi
anticoagul
revers
neurosurgeri
patient
ich
patient
display
complet
inr
correct
immedi
pcc
bolu
allow
anticoagul
patient
manag
rapidli
nonanticoagul
patient
pabing
colleagu
investig
impact
infus
speed
upon
effect
pcc
administr
emerg
revers
vitamin
k
antagonist
therapi
infus
speed
ml
min
use
result
effect
inr
observ
thrombogen
marker
pharmacokinet
record
infus
speed
use
effect
upon
inr
attain
min
plasma
concentr
thrombogen
marker
studi
provid
first
prospect
evid
pcc
rapidli
infus
without
impact
safeti
efficaci
clot
defect
result
sever
liver
damag
due
reduc
level
vitamin
kdepend
coagul
factor
lorenz
colleagu
report
administr
pcc
patient
median
iu
kg
impair
hepat
function
urgent
surgeri
invas
procedur
vivo
recoveri
substitut
coagul
factor
fii
vii
fix
fx
protein
c
clinician
assess
efficaci
either
good
satisfactori
find
conjunct
lack
observ
advers
reaction
led
studi
author
conclud
pcc
administr
cohort
effect
well
toler
period
februari
march
report
number
seriou
ae
record
beriplex
pn
pharmacovigil
databas
low
review
report
ae
publish
clinic
studi
detail
beriplex
pn
administr
show
use
associ
anaphylaxi
allerg
reaction
viru
transmiss
month
posttreat
case
hit
type
ii
low
incid
clinic
overt
thromboembol
complic
figur
line
gener
low
incid
ae
report
administr
fourfactor
pcc
pcc
potent
procoagul
properti
seen
increas
use
emerg
set
anticoagul
revers
treatment
lifethreaten
bleed
howev
product
histor
carri
risk
thrombogen
event
three
main
risk
factor
influenc
thrombot
potenti
patient
receiv
pcc
revers
vitamin
kdepend
anticoagul
identifi
first
predispos
factor
includ
preexist
current
condit
influenc
thrombosi
sinc
patient
receiv
pcc
revers
anticoagul
therapi
underli
tendenc
thrombosi
revers
like
increas
risk
thromboembol
event
secondli
therapeut
factor
concomit
surgeri
level
pcc
dose
administ
increas
risk
final
thrombogenesi
may
influenc
qualiti
pcc
prepar
use
exclus
activ
coagul
factor
inclus
anticoagul
agent
protein
c
z
antithrombin
heparin
particular
import
base
anim
studi
presenc
heparin
antithrombin
suggest
import
effect
neutral
activ
form
fix
fx
vitro
analysi
clot
factor
constitu
pcc
found
fii
prothrombin
primari
thrombogen
compon
present
moreov
ratio
prothrombin
administ
rel
coagul
factor
identifi
major
determin
thrombot
risk
coagul
factor
present
pcc
differ
halfliv
prothrombin
far
longest
h
consequ
recent
review
pcc
thrombogen
colleagu
conclud
prothrombin
accumul
associ
repeat
dose
pcc
primari
determin
thrombot
risk
biochem
comparison
sever
commerci
avail
pcc
identifi
beriplex
pn
well
balanc
four
coagul
factor
present
contain
highest
concentr
therapeut
protein
fx
also
pure
product
test
possess
greatest
thrombin
inhibit
potenti
clinic
evalu
monitor
pharmacokinet
pcc
coagul
factor
healthi
volunt
postberiplex
pn
administr
larg
increas
clot
factor
ii
vii
ix
x
anticoagul
protein
c
observ
importantli
increas
thrombogen
marker
ddimer
observ
clinic
evid
thrombosi
current
articl
repres
updat
data
previous
review
colleagu
case
thromboembol
event
potenti
associ
pcc
administr
includ
total
case
thromboembol
event
possibl
relat
pcc
administr
report
observ
period
report
case
patient
sever
ill
prothrombot
statu
assum
even
direct
causal
relationship
pcc
administr
thromboembol
event
suppos
number
small
respect
number
treatment
one
recent
metaanalysi
threeand
fourfactor
pcc
administ
revers
vitamin
k
antagonist
therapi
identifi
low
quantifi
risk
thromboembol
complic
associ
therapi
overal
rate
thromboembol
event
across
studi
confid
interv
ci
although
slightli
increas
patient
receiv
fourfactor
pcc
ci
report
thrombosi
rate
even
patient
receiv
anticoagul
therapi
high
exampl
orthopaed
surgeri
therefor
import
consid
incid
thromboembol
event
report
pharmacovigil
databas
lower
other
report
like
explan
dispar
relat
underreport
event
patient
receiv
pcc
therapi
import
physician
report
event
consid
may
relat
pcc
administr
build
evid
base
one
problem
report
often
difficult
distinguish
thrombos
result
pcc
administr
due
preexist
unmask
prothrombot
condit
patient
often
receiv
anticoagul
therapi
origin
import
balanc
low
risk
thromboembol
associ
pcc
administr
efficaci
treat
lifethreaten
bleed
recent
prospect
studi
analys
efficaci
safeti
pcc
beriplex
pn
octaplex
prothromplex
w
baxter
deerfield
il
usa
administ
emerg
revers
vitamin
k
antagonist
therapi
due
bleed
need
urgent
surgeri
clinic
efficaci
pcc
therapi
consid
good
patient
administr
associ
low
risk
thromboembol
complic
ci
clinician
point
view
one
might
say
way
reduc
risk
thromboembol
event
could
care
reduc
applic
pcc
accord
clinic
bleed
situat
sinc
regularli
dose
calcul
laboratori
result
administr
clinic
sign
bleed
might
favour
full
correct
inr
seem
necessari
case
furthermor
recent
publish
data
support
use
goaldirect
therapi
base
pointofcar
thromboelastometr
test
reduc
thromboembol
event
pathogen
transmiss
viral
bacteri
prion
protein
transmiss
import
consider
transfus
blood
product
especi
period
widespread
transmiss
human
immunodefici
viru
hiv
emerg
variant
creutzfeldt
jakob
diseas
dentali
colleagu
describ
overal
risk
viral
transmiss
associ
pcc
administr
ci
note
incid
viral
transmiss
report
metaanalysi
relat
four
case
parvoviru
infect
observ
two
studi
document
octaplex
administr
sinc
receiv
market
author
case
pathogen
transmiss
link
beriplex
pn
administr
report
twostep
pathogen
remov
process
manufactur
beriplex
pn
compris
pasteur
nanofiltr
concentr
facilit
viral
inactiv
elimin
respect
process
elimin
virus
test
notabl
influenza
viru
monitor
prion
protein
purif
process
show
significantli
reduc
summari
pharmacovigil
data
connect
publish
clinic
studi
assess
purif
process
show
beriplex
pn
well
toler
relat
transfusiontransmit
pathogen
efficaci
pcc
infus
also
shown
efficaci
correct
inr
compar
establish
clinic
practic
administ
ffp
although
discuss
detail
import
note
two
major
drawback
relat
ffp
infus
high
administr
volum
requir
consequ
slow
rate
infus
given
critic
care
set
pcc
util
acut
complic
associ
anticoagul
therapi
speed
treatment
administ
paramount
consider
treatment
traumarel
bleed
one
set
administr
pcc
increas
retrospect
analysi
trauma
patient
receiv
pcc
therapi
conjunct
fibrinogen
concentr
reveal
improv
surviv
rate
compar
predict
trauma
injuri
sever
score
revis
injuri
sever
classif
score
view
initi
result
clear
requir
prospect
studi
elucid
efficaci
pcc
administr
therapeut
option
treatment
traumarel
bleed
conclus
exist
broad
agreement
across
publish
studi
fourfactor
pcc
efficaci
welltoler
method
correct
coagul
factor
defici
case
vitamin
kdepend
anticoagul
revers
sever
liver
diseas
pharmacovigil
report
detail
yr
administr
beriplex
pn
across
clinic
set
show
product
well
toler
effect
infus
case
viru
transmiss
hit
type
ii
possibl
relat
beriplex
pn
administr
report
extens
data
demonstr
risk
thromboembol
event
low
data
support
clinic
data
commerci
avail
fourfactor
pcc
low
incid
seriou
thromboembol
ae
mitig
efficaci
particular
speed
abl
cessat
bleed
lifethreaten
situat
tem
intern
gmbh
munich
germani
cj
employe
csl
behr
gmbh
marburg
germani
kg
receiv
honoraria
consult
scientif
lectur
csl
behr
gmbh
marburg
germani
tem
intern
gmbh
munich
germani
octapharma
ag
lachen
switzerland
kg
also
clinic
director
tem
intern
